Sequenta, Inc.

21 articles about Sequenta, Inc.

• Adaptive Biotechnologies Banks $94 Million, Buys Bay Area's Sequenta, Inc.

  1/8/2015

• Adaptive Biotechnologies Announces Acquisition Of Sequenta, Inc.

  1/7/2015

• Sequenta, Inc. Enters Agreement With Illumina, Inc. On In Vitro Diagnostic Kit For Sequencing-Based Minimal Residual Disease Testing

  11/17/2014

• Celgene Participates In New Round Of Investment For Sequenta, Inc.

  10/20/2014

• Sequenta, Inc. And Collaborators To Share Clonosight MRD Data In Four Presentations At European Hematology Association

  5/23/2014

• Study Shows Sequenta, Inc.’s Sequencing-Based Minimal Residual Disease (MRD) Detection Technology Has Prognostic Value In Multiple Myeloma

  5/15/2014

• Sequenta, Inc. And Collaborators To Present Lymphoma And Immunotherapy Data At Annual Meeting Of The American Society of Clinical Oncology

  5/15/2014

• Sequenta, Inc.’s Next-Generation Sequencing-Based Minimal Residual Disease (MRD) Quantification Technology Shown To Predict Post-Transplant Relapse And Survival In Adult Acute Lymphoblastic Leukemia (ALL) Patients

  5/8/2014

• Sequenta, Inc.’s Clonosight Test To Be Used By The Dana-Farber Cancer Institute/Acute Lymphoblastic Leukemia (ALL) Consortium

  2/25/2014

• Sequenta, Inc. Issued Third U.S. Patent, Augmenting Its Strong Intellectual Property Portfolio

  2/18/2014

• Sequenta, Inc.’s ClonoSIGHT Test Validated In Multiple Myeloma By Data To Be Presented At Annual Meeting Of The American Society of Hematology

  12/9/2013

• Sequenta, Inc.'s ClonoSIGHT MRD Test Can Detect Relapse Of Diffuse Large B-Cell Lymphoma More Than Seven Months Before CT Scan

  12/9/2013

• Sequenta, Inc. Launches ClonoSIGHT Test In Multiple Myeloma And Diffuse Large B-Cell Lymphoma

  12/5/2013

• Sequenta, Inc. and Collaborators to Present New ClonoSIGHT™ Test Data at Annual Meeting of the American Society of Hematology

  11/7/2013

• Sequenta, Inc. Expands Sample Types Accepted for ClonoSIGHT™ MRD Test for Leukemia and Lymphoma

  9/25/2013

• Sequenta, Inc. Develops Novel Method for Identifying Antigen-Specific T Cells by Combining Conventional Immune Monitoring Assays With High-Throughput Repertoire Sequencing

  9/20/2013

• Sequenta, Inc. and iRepertoire Join Forces on Blood Cancer Testing

  8/8/2013

• Sequenta, Inc. Lands $20 Million

  7/2/2013

• Sequenta, Inc. Collaborators to Present Five Studies Showing the Power of Lymphosight™ Minimal Residual Disease Platform at European Hematology Association

  6/12/2013

• American Society of Clinical Oncology Presentation Shows Sequenta, Inc.'s Lymphosight™ Technology is Highly Predictive of Survival in Multiple Myeloma Patients

  6/3/2013